Skip to main content
Top
Published in: Cancer Cell International 1/2020

01-12-2020 | Hepatocellular Carcinoma | Primary research

Screening and verification of long noncoding RNA promoter methylation sites in hepatocellular carcinoma

Authors: Zhuo Lin, Xiaofeng Ni, Shengjie Dai, Hao Chen, Jianhui Chen, Boda Wu, Jianyang Ao, Keqing Shi, Hongwei Sun

Published in: Cancer Cell International | Issue 1/2020

Login to get access

Abstract

Background

Long noncoding ribonucleic acid (lncRNA) promoter methylation is closely related to the occurrence and development of hepatocellular carcinoma (HCC). Thus, we aim to screen and verify the lncRNA promoter methylation sites associated with overall survival (OS), vascular invasion, pathological grade, and clinical stage in HCC.

Methods

Methylation-related data including clinical characteristic, transcriptome, methylation, and messenger RNA (mRNA) expression were taken from the Cancer Genome Atlas (TCGA) database. The OS, vascular invasion, pathological grade, and clinical stage-related lncRNA promoter methylation models were developed by the least absolute shrinkage and selection operator (LASSO) algorithm based on the lncRNA promoter methylation sites screened via R software. The Kaplan–Meier analysis, the area under the receiver operating characteristic (ROC) curve (AUC), the calibration curve (C-index) were performed to evaluate the performance of these models. Finally, the methylation-specific polymerase chain reaction (MS-PCR) was performed to verify the accuracy of these models based on 146 HCC tissues from our hospital.

Results

A total of 10 methylation sites were included in the OS-related lncRNA promoter methylation model that could effectively divide HCC patients into high-risk and low-risk groups (P < 0.0001) via survival analysis. COX univariable and multivariable regression analysis found that the OS-related model (P < 0.001, 95% CI 1.378–2.942) and T stage (P < 0.001, 95% CI 1.490–3.418) were independent risk factors affecting OS in HCC patients. The vascular invasion-related model contained 8 methylation sites with its AUC value of 0.657; the pathological grade-related model contained 22 methylation sites with its AUC value of 0.797; the clinical stage-related model contained 13 methylation sites with its AUC of 0.724. Target genes corresponded to vascular invasion-related lncRNA promoter methylation sites were involved in many kinds of biological processes in HCC such as PI3K-Akt signaling pathway. The accuracy of the vascular invasion-related model was consistent with our bioinformatics conclusion after being verified via MS-PCR.

Conclusion

The lncRNA promoter methylation sites are closely correlated with the process of HCC and can be utilized to improve the therapy and prognosis of HCC.
Literature
2.
go back to reference Kaplan DE, Mehta R, D’Addeo K, Gade TP, Taddei TH. Transarterial chemoembolization within first 3 months of sorafenib initiation improves overall survival in hepatocellular carcinoma: a retrospective, multi-institutional study with propensity matching. J Vasc Interv Radiol. 2018;29(4):540–9.PubMedPubMedCentralCrossRef Kaplan DE, Mehta R, D’Addeo K, Gade TP, Taddei TH. Transarterial chemoembolization within first 3 months of sorafenib initiation improves overall survival in hepatocellular carcinoma: a retrospective, multi-institutional study with propensity matching. J Vasc Interv Radiol. 2018;29(4):540–9.PubMedPubMedCentralCrossRef
3.
go back to reference Lim C, Bhangui P, Salloum C, Gomez-Gavara C, Lahat E, Luciani A, et al. Impact of time to surgery in the outcome of patients with liver resection for BCLC 0-A stage hepatocellular carcinoma. J Hepatol. 2017;8:270. Lim C, Bhangui P, Salloum C, Gomez-Gavara C, Lahat E, Luciani A, et al. Impact of time to surgery in the outcome of patients with liver resection for BCLC 0-A stage hepatocellular carcinoma. J Hepatol. 2017;8:270.
4.
go back to reference Ren Z, Li A, Jiang J, Zhou L, Yu Z, Lu H, et al. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut. 2018;68:6. Ren Z, Li A, Jiang J, Zhou L, Yu Z, Lu H, et al. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut. 2018;68:6.
5.
go back to reference Gelsinger DR, DiRuggiero J. The non-coding regulatory RNA revolution in Archaea. Genes (Basel). 2018;9:3.CrossRef Gelsinger DR, DiRuggiero J. The non-coding regulatory RNA revolution in Archaea. Genes (Basel). 2018;9:3.CrossRef
6.
go back to reference El Khodiry A, Afify M, El Tayebi HM. Behind the curtain of non-coding RNAs; long non-coding RNAs regulating hepatocarcinogenesis. World J Gastroenterol. 2018;24(5):549–72.PubMedPubMedCentralCrossRef El Khodiry A, Afify M, El Tayebi HM. Behind the curtain of non-coding RNAs; long non-coding RNAs regulating hepatocarcinogenesis. World J Gastroenterol. 2018;24(5):549–72.PubMedPubMedCentralCrossRef
7.
go back to reference Wong CM, Tsang FH, Ng IO. Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications. Nat Rev Gastroenterol Hepatol. 2018;15(3):137–51.PubMedCrossRef Wong CM, Tsang FH, Ng IO. Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications. Nat Rev Gastroenterol Hepatol. 2018;15(3):137–51.PubMedCrossRef
8.
go back to reference Yang S, Sun Z, Zhou Q, Wang W, Wang G, Song J, et al. MicroRNAs, long noncoding RNAs, and circular RNAs: potential tumor biomarkers and targets for colorectal cancer. Cancer Manag Res. 2018;10:2249–57.PubMedPubMedCentralCrossRef Yang S, Sun Z, Zhou Q, Wang W, Wang G, Song J, et al. MicroRNAs, long noncoding RNAs, and circular RNAs: potential tumor biomarkers and targets for colorectal cancer. Cancer Manag Res. 2018;10:2249–57.PubMedPubMedCentralCrossRef
9.
go back to reference Cui M, Xiao Z, Wang Y, Zheng M, Song T, Cai X, et al. Long noncoding RNA HULC modulates abnormal lipid metabolism in hepatoma cells through an miR-9-mediated RXRA signaling pathway. Cancer Res. 2015;75(5):846–57.PubMedCrossRef Cui M, Xiao Z, Wang Y, Zheng M, Song T, Cai X, et al. Long noncoding RNA HULC modulates abnormal lipid metabolism in hepatoma cells through an miR-9-mediated RXRA signaling pathway. Cancer Res. 2015;75(5):846–57.PubMedCrossRef
10.
go back to reference Zhang H, Xing Z, Mani SK, Bancel B, Durantel D, Zoulim F, et al. RNA helicase DEAD box protein 5 regulates Polycomb repressive complex 2/Hox transcript antisense intergenic RNA function in hepatitis B virus infection and hepatocarcinogenesis. Hepatology. 2016;64(4):1033–48.PubMedPubMedCentralCrossRef Zhang H, Xing Z, Mani SK, Bancel B, Durantel D, Zoulim F, et al. RNA helicase DEAD box protein 5 regulates Polycomb repressive complex 2/Hox transcript antisense intergenic RNA function in hepatitis B virus infection and hepatocarcinogenesis. Hepatology. 2016;64(4):1033–48.PubMedPubMedCentralCrossRef
11.
go back to reference Hou Z, Xu X, Fu X, Tao S, Zhou J, Liu S, et al. HBx-related long non-coding RNA MALAT1 promotes cell metastasis via up-regulating LTBP3 in hepatocellular carcinoma. Am J Cancer Res. 2017;7(4):845–56.PubMedPubMedCentral Hou Z, Xu X, Fu X, Tao S, Zhou J, Liu S, et al. HBx-related long non-coding RNA MALAT1 promotes cell metastasis via up-regulating LTBP3 in hepatocellular carcinoma. Am J Cancer Res. 2017;7(4):845–56.PubMedPubMedCentral
12.
13.
go back to reference Chen L, Dzakah EE, Shan G. Targetable long non-coding RNAs in cancer treatments. Cancer Lett. 2018;418:119–24.PubMedCrossRef Chen L, Dzakah EE, Shan G. Targetable long non-coding RNAs in cancer treatments. Cancer Lett. 2018;418:119–24.PubMedCrossRef
14.
go back to reference Liao X, Yang C, Huang R, Han C, Yu T, Huang K, et al. Identification of Potential Prognostic Long Non-Coding RNA Biomarkers for Predicting Survival in Patients with Hepatocellular Carcinoma. Cell Physiol Biochem. 2018;48(5):1854–69.PubMedCrossRef Liao X, Yang C, Huang R, Han C, Yu T, Huang K, et al. Identification of Potential Prognostic Long Non-Coding RNA Biomarkers for Predicting Survival in Patients with Hepatocellular Carcinoma. Cell Physiol Biochem. 2018;48(5):1854–69.PubMedCrossRef
15.
go back to reference Cheng D, Deng J, Zhang B, He X, Meng Z, Li G, et al. LncRNA HOTAIR epigenetically suppresses miR-122 expression in hepatocellular carcinoma via DNA methylation. EBioMedicine. 2018;36:159–70.PubMedPubMedCentralCrossRef Cheng D, Deng J, Zhang B, He X, Meng Z, Li G, et al. LncRNA HOTAIR epigenetically suppresses miR-122 expression in hepatocellular carcinoma via DNA methylation. EBioMedicine. 2018;36:159–70.PubMedPubMedCentralCrossRef
16.
go back to reference Huang F, Chen W, Peng J, Li Y, Zhuang Y, Zhu Z, et al. LncRNA PVT1 triggers Cyto-protective autophagy and promotes pancreatic ductal adenocarcinoma development via the miR-20a-5p/ULK1 Axis. Mol Cancer. 2018;17(1):98.PubMedPubMedCentralCrossRef Huang F, Chen W, Peng J, Li Y, Zhuang Y, Zhu Z, et al. LncRNA PVT1 triggers Cyto-protective autophagy and promotes pancreatic ductal adenocarcinoma development via the miR-20a-5p/ULK1 Axis. Mol Cancer. 2018;17(1):98.PubMedPubMedCentralCrossRef
17.
go back to reference Zhang S, Ma H, Zhang D, Xie S, Wang W, Li Q, et al. LncRNA KCNQ1OT1 regulates proliferation and cisplatin resistance in tongue cancer via miR-211-5p mediated Ezrin/Fak/Src signaling. Cell Death Dis. 2018;9(7):742.PubMedPubMedCentralCrossRef Zhang S, Ma H, Zhang D, Xie S, Wang W, Li Q, et al. LncRNA KCNQ1OT1 regulates proliferation and cisplatin resistance in tongue cancer via miR-211-5p mediated Ezrin/Fak/Src signaling. Cell Death Dis. 2018;9(7):742.PubMedPubMedCentralCrossRef
18.
go back to reference Cancer Genome Atlas Research Network. Electronic address wbe, Cancer Genome Atlas Research N. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell. 2017;169(7):1327–41.CrossRef Cancer Genome Atlas Research Network. Electronic address wbe, Cancer Genome Atlas Research N. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell. 2017;169(7):1327–41.CrossRef
19.
go back to reference Li T, Xie J, Shen C, Cheng D, Shi Y, Wu Z, et al. Upregulation of long noncoding RNA ZEB1-AS1 promotes tumor metastasis and predicts poor prognosis in hepatocellular carcinoma. Oncogene. 2016;35(12):1575–84.PubMedCrossRef Li T, Xie J, Shen C, Cheng D, Shi Y, Wu Z, et al. Upregulation of long noncoding RNA ZEB1-AS1 promotes tumor metastasis and predicts poor prognosis in hepatocellular carcinoma. Oncogene. 2016;35(12):1575–84.PubMedCrossRef
20.
go back to reference Sun H, Wang S. Penalized logistic regression for high-dimensional DNA methylation data with case-control studies. Bioinformatics. 2012;28(10):1368–75.PubMedPubMedCentralCrossRef Sun H, Wang S. Penalized logistic regression for high-dimensional DNA methylation data with case-control studies. Bioinformatics. 2012;28(10):1368–75.PubMedPubMedCentralCrossRef
21.
go back to reference Liu H, Song G, Zhou L, Hu X, Liu M, Nie J, et al. Compared analysis of LncRNA expression profiling in pdk1 gene knockout mice at two time points. Cell Physiol Biochem. 2013;32(5):1497–508.PubMedCrossRef Liu H, Song G, Zhou L, Hu X, Liu M, Nie J, et al. Compared analysis of LncRNA expression profiling in pdk1 gene knockout mice at two time points. Cell Physiol Biochem. 2013;32(5):1497–508.PubMedCrossRef
22.
go back to reference Zheng Z, Zhao F, Zhu D, Han J, Chen H, Cai Y, et al. Long non-coding RNA LUCAT1 promotes proliferation and invasion in clear cell renal cell carcinoma through AKT/GSK-3beta signaling pathway. Cell Physiol Biochem. 2018;48(3):891–904.PubMedCrossRef Zheng Z, Zhao F, Zhu D, Han J, Chen H, Cai Y, et al. Long non-coding RNA LUCAT1 promotes proliferation and invasion in clear cell renal cell carcinoma through AKT/GSK-3beta signaling pathway. Cell Physiol Biochem. 2018;48(3):891–904.PubMedCrossRef
23.
go back to reference Tang Q, Zheng X, Zhang J. Long non-coding RNA CRNDE promotes heptaocellular carcinoma cell proliferation by regulating PI3K/Akt/beta-catenin signaling. Biomed Pharmacother. 2018;103:1187–93.PubMedCrossRef Tang Q, Zheng X, Zhang J. Long non-coding RNA CRNDE promotes heptaocellular carcinoma cell proliferation by regulating PI3K/Akt/beta-catenin signaling. Biomed Pharmacother. 2018;103:1187–93.PubMedCrossRef
24.
go back to reference Hou Y, Yu Z, Tam NL, Huang S, Sun C, Wang R, et al. Exosome-related lncRNAs as predictors of HCC patient survival: a prognostic model. Am J Transl Res. 2018;10(6):1648–62.PubMedPubMedCentral Hou Y, Yu Z, Tam NL, Huang S, Sun C, Wang R, et al. Exosome-related lncRNAs as predictors of HCC patient survival: a prognostic model. Am J Transl Res. 2018;10(6):1648–62.PubMedPubMedCentral
25.
go back to reference Zheng H, Yang S, Yang Y, Yuan SX, Wu FQ, Wang LL, et al. Epigenetically silenced long noncoding-SRHC promotes proliferation of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2015;141(7):1195–203.PubMedCrossRef Zheng H, Yang S, Yang Y, Yuan SX, Wu FQ, Wang LL, et al. Epigenetically silenced long noncoding-SRHC promotes proliferation of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2015;141(7):1195–203.PubMedCrossRef
26.
go back to reference Braconi C, Kogure T, Valeri N, Huang N, Nuovo G, Costinean S, et al. microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. Oncogene. 2011;30(47):4750–6.PubMedPubMedCentralCrossRef Braconi C, Kogure T, Valeri N, Huang N, Nuovo G, Costinean S, et al. microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. Oncogene. 2011;30(47):4750–6.PubMedPubMedCentralCrossRef
27.
go back to reference Zhang J, Fan D, Jian Z, Chen GG, Lai PB. Cancer specific long noncoding RNAs show differential expression patterns and competing endogenous RNA potential in hepatocellular carcinoma. PLoS ONE. 2015;10(10):e0141042.PubMedPubMedCentralCrossRef Zhang J, Fan D, Jian Z, Chen GG, Lai PB. Cancer specific long noncoding RNAs show differential expression patterns and competing endogenous RNA potential in hepatocellular carcinoma. PLoS ONE. 2015;10(10):e0141042.PubMedPubMedCentralCrossRef
28.
go back to reference Ardelt MA, Frohlich T, Martini E, Muller M, Kanitz V, Atzberger C, et al. Inhibition of cyclin-dependent kinase 5: a strategy to improve sorafenib response in hepatocellular carcinoma therapy. Hepatology. 2019;69(1):376–93.PubMedCrossRef Ardelt MA, Frohlich T, Martini E, Muller M, Kanitz V, Atzberger C, et al. Inhibition of cyclin-dependent kinase 5: a strategy to improve sorafenib response in hepatocellular carcinoma therapy. Hepatology. 2019;69(1):376–93.PubMedCrossRef
29.
go back to reference Wang YD, Sun XJ, Yin JJ, Yin M, Wang W, Nie ZQ, et al. Long non-coding RNA FEZF1-AS1 promotes cell invasion and epithelial-mesenchymal transition through JAK2/STAT3 signaling pathway in human hepatocellular carcinoma. Biomed Pharmacother. 2018;106:134–41.PubMedCrossRef Wang YD, Sun XJ, Yin JJ, Yin M, Wang W, Nie ZQ, et al. Long non-coding RNA FEZF1-AS1 promotes cell invasion and epithelial-mesenchymal transition through JAK2/STAT3 signaling pathway in human hepatocellular carcinoma. Biomed Pharmacother. 2018;106:134–41.PubMedCrossRef
30.
go back to reference Fan H, Lv P, Mu T, Zhao X, Liu Y, Feng Y, et al. LncRNA n335586/miR-924/CKMT1A axis contributes to cell migration and invasion in hepatocellular carcinoma cells. Cancer Lett. 2018;429:89–99.PubMedCrossRef Fan H, Lv P, Mu T, Zhao X, Liu Y, Feng Y, et al. LncRNA n335586/miR-924/CKMT1A axis contributes to cell migration and invasion in hepatocellular carcinoma cells. Cancer Lett. 2018;429:89–99.PubMedCrossRef
31.
go back to reference Huang G, Jiang H, Lin Y, Wu Y, Cai W, Shi B, et al. lncAKHE enhances cell growth and migration in hepatocellular carcinoma via activation of NOTCH2 signaling. Cell Death Dis. 2018;9(5):487.PubMedPubMedCentralCrossRef Huang G, Jiang H, Lin Y, Wu Y, Cai W, Shi B, et al. lncAKHE enhances cell growth and migration in hepatocellular carcinoma via activation of NOTCH2 signaling. Cell Death Dis. 2018;9(5):487.PubMedPubMedCentralCrossRef
32.
go back to reference Gou X, Zhao X, Wang Z. Long noncoding RNA PVT1 promotes hepatocellular carcinoma progression through regulating miR-214. Cancer Biomark. 2017;20(4):511–9.PubMedCrossRef Gou X, Zhao X, Wang Z. Long noncoding RNA PVT1 promotes hepatocellular carcinoma progression through regulating miR-214. Cancer Biomark. 2017;20(4):511–9.PubMedCrossRef
Metadata
Title
Screening and verification of long noncoding RNA promoter methylation sites in hepatocellular carcinoma
Authors
Zhuo Lin
Xiaofeng Ni
Shengjie Dai
Hao Chen
Jianhui Chen
Boda Wu
Jianyang Ao
Keqing Shi
Hongwei Sun
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2020
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-020-01407-4

Other articles of this Issue 1/2020

Cancer Cell International 1/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine